Literature DB >> 26065472

Advances and prospects in adoptive cell transfer therapy for ovarian cancer.

Katarzyna Urbanska1, Daniel J Powell1,2.   

Abstract

Entities:  

Keywords:  TCR; TILs; adoptive T-cell therapy; chimeric antigen receptor; gene engineering; immunotherapy; ovarian cancer

Mesh：

Year:  2015        PMID： 26065472      PMCID： PMC4851244          DOI： 10.2217/imt.15.21

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  23 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.

Authors:  Cyrille J Cohen; Zhili Zheng; Regina Bray; Yangbing Zhao; Linda A Sherman; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

3.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

4.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors:  Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151

7.  Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Authors:  Marij J P Welters; Gemma G Kenter; Sytse J Piersma; Annelies P G Vloon; Margriet J G Löwik; Dorien M A Berends-van der Meer; Jan W Drijfhout; A Rob P M Valentijn; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Rienk Offringa; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Authors:  Paul Sabbatini; Takemasa Tsuji; Luis Ferran; Erika Ritter; Christine Sedrak; Kevin Tuballes; Achim A Jungbluth; Gerd Ritter; Carol Aghajanian; Katherine Bell-McGuinn; Martee L Hensley; Jason Konner; William Tew; David R Spriggs; Eric W Hoffman; Ralph Venhaus; Linda Pan; Andres M Salazar; Catherine Magid Diefenbach; Lloyd J Old; Sacha Gnjatic
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

10.  Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Daniel J Powell; Cheryl L Chiang; Janos Tanyi; Sarah Kim; Marnix Bosch; Kathy Montone; Rosemarie Mick; Bruce L Levine; Drew A Torigian; Carl H June; George Coukos
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110
View more
  4 in total

1.  Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.

Authors:  Dmitriy Zamarin; Robert A Burger; Michael W Sill; Daniel J Powell; Heather A Lankes; Michael D Feldman; Oliver Zivanovic; Camille Gunderson; Emily Ko; Cara Mathews; Sudarshan Sharma; Andrea R Hagemann; Samir Khleif; Carol Aghajanian
Journal:  J Clin Oncol       Date:  2020-04-10       Impact factor: 44.544

Review 2.  Cell therapies in ovarian cancer.

Authors:  Apostolos Sarivalasis; Matteo Morotti; Arthur Mulvey; Martina Imbimbo; George Coukos
Journal:  Ther Adv Med Oncol       Date:  2021-04-22       Impact factor: 8.168

Review 3.  Immunotherapy Advances for Epithelial Ovarian Cancer.

Authors:  Erin G Hartnett; Julia Knight; Mackenzy Radolec; Ronald J Buckanovich; Robert P Edwards; Anda M Vlad
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

Review 4.  Nature of tumour rejection antigens in ovarian cancer.

Authors:  Muzamil Y Want; Amit A Lugade; Sebastiano Battaglia; Kunle Odunsi
Journal:  Immunology       Date:  2018-06-13       Impact factor: 7.215
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.